Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KPC000154
- Development stage
- Phase 1
- Lead developer
- Kunming Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KPC000154 is an oral small molecule drug that acts as a thyroid hormone receptor beta (THR-β) agonist. It is being developed primarily for the treatment of nonalcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). By selectively activating THR-β, KPC000154 aims to improve NASH by increasing hepatic fat metabolism and reducing liver fat accumulation. The drug is classified as a Class 1 innovative chemical entity and has entered clinical trials following approval from Chinese regulatory authorities. KPC000154 was independently developed by Kunming Pharmaceutical Group, also known as KPC Pharmaceuticals[1][2][4][5][6].
02
Targets
THRB (Thyroid hormone receptor beta)
Beyond the preview
Go deeper on KPC000154.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KPC000154.